2023
Reductions in synaptic marker SV2A in early-course Schizophrenia
Yoon J, Zhang Z, Mormino E, Davidzon G, Minzenberg M, Ballon J, Kalinowski A, Hardy K, Naganawa M, Carson R, Khalighi M, Park J, Levinson D, Chin F. Reductions in synaptic marker SV2A in early-course Schizophrenia. Journal Of Psychiatric Research 2023, 161: 213-217. PMID: 36934603, DOI: 10.1016/j.jpsychires.2023.02.026.Peer-Reviewed Original ResearchConceptsChronic patientsSynaptic pruningStage of illnessEarly course patientsEarly course schizophreniaSeverity of delusionsWidespread reductionMajor disease mechanismsSynaptic deficitsSynaptic markersSynaptic eliminationPET scansFormal onsetBrain regionsSignificant positive correlationPatientsSchizophrenia studiesSchizophreniaDisease mechanismsCognitive performanceIllnessEarly phaseSpecific bindingPresent studyPositive correlation
2021
In vivo evidence of lower synaptic vesicle density in schizophrenia
Radhakrishnan R, Skosnik PD, Ranganathan M, Naganawa M, Toyonaga T, Finnema S, Hillmer AT, Esterlis I, Huang Y, Nabulsi N, Carson RE, D’Souza D. In vivo evidence of lower synaptic vesicle density in schizophrenia. Molecular Psychiatry 2021, 26: 7690-7698. PMID: 34135473, DOI: 10.1038/s41380-021-01184-0.Peer-Reviewed Original ResearchMeSH KeywordsBrainHumansNerve Tissue ProteinsPositron-Emission TomographySchizophreniaSynaptic VesiclesConceptsSynaptic vesicle densityHealthy controlsVesicle densityHigh-resolution research tomographySynaptic densitySCZ patientsVivo measuresNovel positron emission tomography (PET) ligandGender-matched healthy controlsCumulative antipsychotic exposurePositron emission tomography (PET) ligandSynaptic spine densityPsychosis symptom severityGray matter volumeJ bindingAntipsychotic exposureSpine densityDisease progressionFrontal cortexOccipital cortexTomography ligandTemporal cortexAnterior cingulateVivo findingsParietal cortex
2018
Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects
D’Souza D, Carson RE, Driesen N, Johannesen J, Ranganathan M, Krystal JH, Ahn K, Bielen K, Carbuto M, Deaso E, D’Souza D, Ranganathan M, Naganawa M, Ranganathan M, D’Souza D, Nabulsi N, Zheng M, Lin S, Huang Y, Carson R, Driesen N, Ahn K, Morgan P, Suckow R, He G, McCarthy G, Krystal J, Johannesen J, Kenney J, Gelernter J, Gueorguieva R, Pittman B. Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects. Biological Psychiatry 2018, 84: 413-421. PMID: 29499855, PMCID: PMC6068006, DOI: 10.1016/j.biopsych.2017.12.019.Peer-Reviewed Original ResearchMeSH KeywordsAdultAzabicyclo CompoundsBrainCognitive DysfunctionDose-Response Relationship, DrugDouble-Blind MethodFemaleGlycine Plasma Membrane Transport ProteinsHumansImidazolesKetamineLong-Term PotentiationMagnetic Resonance ImagingMaleMemory, Short-TermMiddle AgedPositron-Emission TomographySchizophreniaYoung AdultConceptsHealthy control subjectsLong-term potentiationSchizophrenia patientsControl subjectsCognitive impairmentClinical trialsGlyT1 occupancyN-methyl-D-aspartate receptor functionGlycine transporter-1 inhibitorKetamine-induced disruptionKetamine-induced effectsFunctional magnetic resonance imagingMagnetic resonance imagingPositron emission tomographyMemory-related activationF-MKSubstudy 1Schizophrenia subjectsResonance imagingReceptor functionCortical regionsEmission tomographyTarget engagementPotentiationSchizophrenia
2015
Reduced Brain Cannabinoid Receptor Availability in Schizophrenia
Ranganathan M, Cortes-Briones J, Radhakrishnan R, Thurnauer H, Planeta B, Skosnik P, Gao H, Labaree D, Neumeister A, Pittman B, Surti T, Huang Y, Carson RE, D’Souza D. Reduced Brain Cannabinoid Receptor Availability in Schizophrenia. Biological Psychiatry 2015, 79: 997-1005. PMID: 26432420, PMCID: PMC4884543, DOI: 10.1016/j.biopsych.2015.08.021.Peer-Reviewed Original ResearchConceptsHealthy control subjectsSCZ subjectsCB1R availabilityECB systemMale healthy control subjectsBody mass indexAge-matched male healthy control subjectsPathophysiology of schizophreniaPositron emission tomographyPosterior cingulate cortexPresence of abnormalitiesMass indexControl subjectsEndocannabinoid systemTobacco useReceptor availabilityCingulate cortexEmission tomography dataBrain regionsEmission tomographySelective radiotracerVivo measuresRegional volumesSchizophreniaPositron emission tomography data
2000
Measurement of dopamine release with continuous infusion of [11C]raclopride: optimization and signal-to-noise considerations.
Watabe H, Endres CJ, Breier A, Schmall B, Eckelman WC, Carson RE. Measurement of dopamine release with continuous infusion of [11C]raclopride: optimization and signal-to-noise considerations. Journal Of Nuclear Medicine 2000, 41: 522-30. PMID: 10716328.Peer-Reviewed Original ResearchConceptsOptimal timingAdministration of amphetamineReceptor imaging studiesHuman dataContinuous infusionDopamine releaseOptimal scan timeHealthy volunteersHuman studiesSynaptic dopamineImaging studiesPET studiesDopamine responsePercentage changeCareful assessmentStatistical significanceDeltaBPInfusionMeasurement of changesIndirect measureActivity curvesPrePatients
1997
Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method
Breier A, Su T, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proceedings Of The National Academy Of Sciences Of The United States Of America 1997, 94: 2569-2574. PMID: 9122236, PMCID: PMC20129, DOI: 10.1073/pnas.94.6.2569.Peer-Reviewed Original ResearchConceptsSynaptic dopamine concentrationsDopamine concentrationsDopamine outflowDopamine levelsStriatal extracellular dopamine levelsBinding reductionPositron emission tomography radioligandExtracellular dopamine levelsSynaptic dopamine levelsAmphetamine-induced changesNonhuman primate studiesPositron emission tomography (PET) methodDopamine overactivityPatients elevationNovel brain imaging methodVivo microdialysisAmphetamine doseDopamine receptorsClinical studiesDopamine releasePreclinical studiesHealthy volunteersBrain imaging methodsDopamine increasesTomography radioligand